G. Dranitsaris

发表

The use of complementary and alternative medicines among patients with locally advanced breast cancer – a descriptive study

B. Chui, L. Helyer, S. Chin, 2006, BMC Cancer.

Abraxane® versus Taxol® for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective

G. Dranitsaris, S. Kaura, Bo Yu, 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Clinical trial design in biosimilar drug development

G. Dranitsaris, E. Hatzimichael, K. Dorward, 2013, Investigational New Drugs.

Cost-effectiveness of chemotherapy for nonsmall-cell lung cancer

G. Dranitsaris, W. Evans, Wayne Cottrell, 2002, Current opinion in oncology.

Management of Diabetes Mellitus Defining the Role of Insulin Lispro Mix75/25 (Humalog ® Mix75/25™)

G. Dranitsaris, E. Torlone, A. Krentz, 2001 .

Meta-Analyses of Placebo-Controlled Trials of Acamprosate for the Treatment of Alcohol Dependence: Impact of the Combined Pharmacotherapies and Behavior Interventions Study

G. Dranitsaris, P. Selby, J. Negrete, 2009, Journal of addiction medicine.

The cost of blood transfusions in cancer patients: a reanalysis of a Canadian economic evaluation

G. Dranitsaris, 2000 .

Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

G. Dranitsaris, M. Clemons, M. Clemons, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Recent developments in bisphosphonates for patients with metastatic breast cancer

G. Dranitsaris, M. Clemons, M. C. Gainford, 2005, BMJ : British Medical Journal.

Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib

M. Lacouture, G. Dranitsaris, M. Vincent, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Risk prediction models for chemotherapy-induced nausea and vomiting: almost ready for prime time?

G. Dranitsaris, M. Clemons, 2014, Supportive Care in Cancer.

Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis

A. Shah, G. Dranitsaris, J. Maroun, 2005, Supportive Care in Cancer.

Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea.

A. Shah, G. Dranitsaris, J. Maroun, 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea

G. Dranitsaris, M. Vincent, S. Dowden, 2007, Current oncology.

Preference weights for chemotherapy side effects from the perspective of women with breast cancer

G. Dranitsaris, M. Clemons, R. Segal, 2013, Breast Cancer Research and Treatment.

Survival Differences Observed in Metastatic Breast Cancer Patients Treated With Capecitabine When Compared With Vinorelbine After Pretreatment With Anthracycline and Taxane

J. Mackey, S. Verma, G. Dranitsaris, 2007, American journal of clinical oncology.

Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness

G. Dranitsaris, Lesley G. Shane, S. Woodruff, 2017, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis

G. Dranitsaris, M. Crowther, S. Woodruff, 2017, ClinicoEconomics and outcomes research : CEOR.

What are cancer patients willing to pay for prophylactic epoetin alfa?

G. Dranitsaris, A. Ortega, A. Puodziunas, 1998, Cancer.

Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma

G. Dranitsaris, D. Liew, P. McEwan, 2020, ClinicoEconomics and outcomes research : CEOR.

Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma

G. Dranitsaris, D. Liew, P. McEwan, 2019, Journal of medical economics.

Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists

G. Dranitsaris, M. Clemons, E. Amir, 2011, Supportive Care in Cancer.

A RANDOMIZED TRIAL TO MEASURE THE OPTIMAL ROLE OF THE PHARMACIST IN PROMOTING EVIDENCE-BASED ANTIBIOTIC USE IN ACUTE CARE HOSPITALS

G. Dranitsaris, A. McGeer, D. Spizzirri, 2001, International Journal of Technology Assessment in Health Care.

Genetic profile sets: differences and preferences

M. Dowsett, F. O'Malley, G. Dranitsaris, 2009, Breast Cancer Research.

Systemic treatment of bone metastases from breast cancer: is it all that it's cracked up to be?

G. Dranitsaris, M. Clemons, M. C. Gainford, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Positron Emission Tomography Paradigm Fuzzier Than Reported

G. Hortobagyi, G. Dranitsaris, M. Clemons, 2005 .

An application review for practitioners

G. Dranitsaris, M. Pharm, 2002 .

A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients

G. Dranitsaris, S. Blau, M. Moezi, 2022, Supportive Care in Cancer.

A Community Hospital-Based Study: A Prespecified Neutrophil Count with Adjuvant mFOLFOX6 Associated with Increased Delays, Increased G-CSF Use, and Reduced Dose Intensity

G. Dranitsaris, J. Chiarotto, 2021, Cancer management and research.

FOLFOX chemotherapy can safely be given to neutropenic patients with early-stage colorectal cancer for higher dose intensity and fewer visits

G. Dranitsaris, J. Chiarotto, 2016, Supportive Care in Cancer.

Improving patient access to cancer drugs in India: Using economic modeling to estimate a more affordable drug cost based on measures of societal value

G. Dranitsaris, I. Truter, M. Lubbe, 2011, International Journal of Technology Assessment in Health Care.

A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe

G. Dranitsaris, I. Truter, M. Lubbe, 2012, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

The development of a value based pricing index for new drugs in metastatic colorectal cancer.

G. Dranitsaris, I. Truter, M. Lubbe, 2011, European journal of cancer.

Bevacizumab in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer: an assessment of safety and efficacy in the province of Newfoundland and Labrador.

M. Leblanc, G. Dranitsaris, R. Abbott, 2010, Current oncology.

A Multinational Study to Measure the Value that Patients with Cancer Place on Improved Emesis Control Following Cisplatin Chemotherapy

R. Labianca, G. Dranitsaris, M. Spinthouri, 2012, PharmacoEconomics.

Clinical and Economic Considerations of Empirical Antibacterial Therapy of Febrile Neutropenia in Cancer

G. Dranitsaris, 1999, PharmacoEconomics.

Cost-Benefit Analysis of Prophylactic Granulocyte Colony-Stimulating Factor During CHOP Antineoplastic Therapy for Non-Hodgkin’s Lymphoma

G. Dranitsaris, I. Quirt, C. Altmayer, 1997, PharmacoEconomics.

Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction model.

S. Verma, G. Dranitsaris, M. Clemons, 2005, The Lancet. Oncology.

Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study

G. Dranitsaris, D. Warr, P. Leung, 2001, Supportive Care in Cancer.

A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron

G. Dranitsaris, D. Warr, A. Puodziunas, 1995, Supportive Care in Cancer.

Clinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: experience from a single academic cancer centre.

G. Dranitsaris, J. Fraser, S. Dent, 2013, Current oncology.

Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation

G. Dranitsaris, D. Liew, P. McEwan, 2017, PharmacoEconomics.

Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting.

H. Rugo, G. Dranitsaris, S. Gluck, 2015, Clinical therapeutics.

Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost.

G. Dranitsaris, A. Ellis, 2014, Journal of evaluation in clinical practice.

Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment

G. Dranitsaris, Lesley G. Shane, S. Woodruff, 2016, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer.

G. Dranitsaris, M. Clemons, C. Simmons, 2009, Clinical breast cancer.

The price function of toxicity.

G. Dranitsaris, M. Vincent, 2009, The Lancet. Oncology.

Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa

G. Dranitsaris, J. Burger, M. Lubbe, 2016, PharmacoEconomics.

JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality

A. Farcomeni, C. Kutter, S. Burley, 2020, Science Advances.

Measuring Treatment Preferences and Willingness to Pay for Docetaxel in Advanced Ovarian Cancer

G. Dranitsaris, Wayne Cottrell, Julia Elia-Pacitti, 2012, PharmacoEconomics.

Ibrutinib-associated Dermatologic Toxicities: A Systematic Review and Meta-analysis.

M. Lacouture, G. Dranitsaris, A. Mato, 2022, Critical reviews in oncology/hematology.

Bisphosphonate use for the management of breast cancer patients with bone metastases: A survey of Canadian Medical Oncologists

Annemarie Cesta, S. Verma, G. Dranitsaris, 2004, Supportive Care in Cancer.

Randomized Feasibility Study of De-escalated (Every 12 wk) Versus Standard (Every 3 to 4 wk) Intravenous Pamidronate in Women With Low-risk Bone Metastases From Breast Cancer

A. Laupacis, I. Tannock, G. Tomlinson, 2013, American journal of clinical oncology.

A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer

D. Cella, G. Dranitsaris, M. Clemons, 2015, Breast Cancer Research and Treatment.

Urinary N-telopeptide is a rapid predictor of response to and palliative benefit from bisphosphonate therapy in patients with metastatic breast cancer.

G. Dranitsaris, M. Clemons, D. Cole, 2007, Supportive cancer therapy.

Instructions to Authors

G. Dranitsaris, M. Clemons, C. Simmons, 2006, Neuromuscular Disorders.

Zoledronic acid versus pamidronate as palliative therapy in cancer patients: A Canadian time and motion analysis

K. Schulman, G. Dranitsaris, Liana DesHarnais Bruce, 2001 .

Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective

G. Dranitsaris, S. Kaura, Bo Yu, 2015, ClinicoEconomics and outcomes research : CEOR.

Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications

G. Dranitsaris, T. Crook, E. Hatzimichael, 2012, Leukemia & lymphoma.

A Clinical and Economic Evaluation of Red Blood Cell Transfusions in Patients Receiving Cancer Chemotherapy

G. Dranitsaris, A. Ortega, A. Puodziunas, 1998, International Journal of Technology Assessment in Health Care.

Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients

G. Dranitsaris, E. Hatzimichael, 2012, Supportive Care in Cancer.

Altered calcium metabolism in patients on long-term bisphosphonate therapy for metastatic breast cancer.

G. Dranitsaris, M. Clemons, E. Amir, 2009, Anticancer research.

Opioid Prescribing in Canada following the Legalization of Cannabis: A Clinical and Economic Time-Series Analysis

G. Dranitsaris, B. Pohlmann-Eden, C. DeAngelis, 2021, Applied Health Economics and Health Policy.

What is a new drug worth? An innovative model for performance-based pricing.

G. Dranitsaris, K. Dorward, H. Schipper, 2015, European journal of cancer care.

Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer

G. Dranitsaris, M. Clemons, E. Amir, 2009, Journal of Clinical Pathology.

CMAR_A_307713 4087..4094

G. Dranitsaris, J. Chiarotto, 2021 .

A phase 2 trial exploring the effects of high‐dose (10,000 IU/day) vitamin D3 in breast cancer patients with bone metastases

G. Dranitsaris, M. Clemons, R. Vieth, 2010, Cancer.

G. Dranitsaris, S. Blau, M. Moezi, 2022, Supportive Care in Cancer.

Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors

G. Dranitsaris, M. Clemons, Stephanie Smith, 2016, Supportive Care in Cancer.

Dalteparin versus Warfarin for the Prevention of Recurrent Venous Thromboembolic Events in Cancer Patients

G. Dranitsaris, M. Vincent, M. Crowther, 2012, PharmacoEconomics.

Does prolonging the time to renal cancer surgery affect long-term cancer control: a systematic review of the literature.

B. Donnelly, G. Dranitsaris, N. Fleshner, 2006, The Canadian journal of urology.

Lenalidomide versus bortezomib: an indirect comparison

G. Dranitsaris, S. Kaura, 2014 .

Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis

G. Dranitsaris, A. McBride, E. Elquza, 2019, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria

G. Dranitsaris, G. Stemer, Lesley G. Shane, 2017, Supportive Care in Cancer.

Pharmacoeconomic Analysis of Fondaparinux Versus Enoxaparin for the Prevention of Thromboembolic Events in Orthopedic Surgery Patients

G. Dranitsaris, S. Kahn, Jeffrey S. Ginsberg, 2004, American journal of cardiovascular drugs : drugs, devices, and other interventions.

Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis

G. Dranitsaris, H. Khoury, 2011, Supportive Care in Cancer.

Development of a repeated-measures predictive model and clinical risk score for mortality in ventilated COVID-19 patients

I. Bogoch, S. Mehta, G. Dranitsaris, 2021, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.

nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial

W. Gradishar, G. Dranitsaris, R. Coleman, 2010, Breast Cancer Research and Treatment.

Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate

A. Oza, G. Dranitsaris, P. Leung, 2000, Anti-cancer drugs.

Prospective Study Evaluating the Impact of Tissue Conﬁrmation of Metastatic Disease in Patients With Breast Cancer

A. Laupacis, I. Tannock, G. Tomlinson, 2012 .

Meta-Regression Analysis to Indirectly Compare Prophylaxis With Dalteparin or Enoxaparin in Patients at High Risk for Venous Thromboembolic Events

V. Jelinčić, G. Dranitsaris, Y. Choe, 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Patients at High Risk for Venous Thromboembolic Events Meta-Regression Analysis to Indirectly Compare Prophylaxis With Dalteparin or Enoxaparin in

V. Jelinčić, G. Dranitsaris, Y. Choe, 2012 .

Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacement

V. Jelinčić, G. Dranitsaris, Y. Choe, 2011, Thrombosis journal.

Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia

G. Dranitsaris, J. Chiarotto, 2013, Supportive Care in Cancer.

Clinical utility of a prediction tool to differentiate between breast cancer patients at high or low risk of chemotherapy-induced nausea and vomiting

G. Dranitsaris, M. Clemons, L. Vandermeer, 2021, Supportive Care in Cancer.

Von Hippel-Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease.

G. Dranitsaris, T. Crook, E. Hatzimichael, 2009, Clinical lymphoma & myeloma.

Improving the Cost Efficiency of PD-1/PD-L1 Inhibitors for Advanced Urothelial Carcinoma: A Major Role for Precision Medicine?

G. Sonpavde, G. Dranitsaris, A. Necchi, 2018, European urology.

Pre-operative exercise and pyrexia as modifying factors in malignant hyperthermia (MH)

A. Bjorksten, G. Dranitsaris, N. Voermans, 2021, Neuromuscular Disorders.

Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study.

G. Dranitsaris, M. Clemons, M. Trudeau, 2007, The journal of supportive oncology.

A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer

M. Dowsett, F. O'Malley, G. Dranitsaris, 2009, Breast Cancer Research and Treatment.

Cost Utility Analysis of First-Line Hormonal Therapy in Advanced Breast Cancer: Comparison of Two Aromatase Inhibitors to Tamoxifen

G. Dranitsaris, M. Trudeau, S. Verma, 2003, American journal of clinical oncology.

Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy-single-centre experience.

G. Dranitsaris, M. Clemons, S. Dent, 2012, Current oncology.

What is the best chemotherapy treatment option for anthracycline and taxane pretreated metastatic breast cancer?

J. Mackey, S. Verma, G. Dranitsaris, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment Preference for Alzheimer’s Disease: A Multicriteria Decision Analysis with Caregivers, Neurologists, and Payors

G. Dranitsaris, P. Neumann, Quanwu Zhang, 2022, Neurology and Therapy.

I Advances in prevention , diagnosis and genetics S 1 Identifying and assessing women at high risk for breast cancer

M. Dowsett, F. O'Malley, G. Dranitsaris, 2009 .

A structured group exercise program for patients with metastatic cancer receiving chemotherapy and CTNNB1 (β-catenin) as a biomarker of exercise efficacy

G. Dranitsaris, J. Chiarotto, R. Akbarali, 2017, Cancer management and research.

A vancomycin drug use evaluation and economic analysis in a cancer treatment centre.

G. Dranitsaris, A. McGreer, N. J. Pilla, 1994, The Canadian journal of hospital pharmacy.

Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspective

G. Dranitsaris, D. Spaner, R. Foley, 1998, Bone Marrow Transplantation.

ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery.

E. Perez, D. Gandara, G. Dranitsaris, 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature

G. Dranitsaris, B. Zanke, E. Green, 2005, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Does prolonging the time to bladder cancer surgery affect long-term cancer control: a systematic review of the literature.

G. Dranitsaris, N. Fleshner, J. Tsihlias, 2006, The Canadian journal of urology.

Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer.

Mark Clemons, Ian F Tannock, Andreas Laupacis, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Economic Analysis of Fluconazole versus Amphotericin B for the Treatment of Candidemia in Non-Neutropenic Patients

Mark A. Miller, J. Singer, G. Dranitsaris, 1998, PharmacoEconomics.

Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design.

Jeff Myers, G. Dranitsaris, M. Clemons, 2009, Clinical breast cancer.

The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy

P. Gascón, S. Verma, G. Dranitsaris, 2007, Supportive Care in Cancer.

Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions

G. Dranitsaris, T. Crook, N. Syed, 2011, Annals of Hematology.

Comparing the results of bisphosphonate use in clinical trials with actual practice: a case of apples and oranges?

G. Dranitsaris, M. Clemons, M. Vanhuyse, 2006, Current oncology.

CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes.

G. Dranitsaris, E. Hatzimichael, I. Georgiou, 2010, Leukemia research.

Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting.

G. Dranitsaris, M. Clemons, P. Wheatley‐Price, 2012, Current oncology.

An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer.

J. D. Thomas, G. Sonpavde, G. Dranitsaris, 2021, Urologic oncology.

Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.

S. Verma, G. Dranitsaris, M. Clemons, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis

G. Dranitsaris, G. Adunlin, J. Cyrus, 2015, Breast Cancer Research and Treatment.

Evaluating the impact of bevacizumab maintenance therapy on overall survival in advanced non-small-cell lung cancer.

G. Dranitsaris, Sachdev P. Thomas, E. Yu, 2013, Clinical lung cancer.

Advances in Cancer Therapeutics and Patient Access to New Drugs

G. Dranitsaris, W. Evans, I. Truter, 2011, PharmacoEconomics.

A country level analysis measuring the impact of government actions, country preparedness and socioeconomic factors on COVID-19 mortality and related health outcomes

G. Dranitsaris, S. Riazi, J. Bartoszko, 2020, EClinicalMedicine.

Defining optimal control of chemotherapy-induced nausea and vomiting—based on patients’ experience

G. Dranitsaris, B. Hutton, M. Clemons, 2015, Supportive Care in Cancer.

Study of specific genetic and epigenetic variables in multiple myeloma

G. Dranitsaris, T. Crook, N. Syed, 2010, Leukemia & lymphoma.

Drug tendering: drug supply and shortage implications for the uptake of biosimilars

Carol F. Kirchhoff, G. Dranitsaris, R. Popovian, 2017, ClinicoEconomics and outcomes research : CEOR.

Clinico‐morphological features of BRAF inhibition–induced proliferative skin lesions in cancer patients

A. Marghoob, M. Lacouture, G. Dranitsaris, 2015, Cancer.

Letrozole or anastrozole for the prevention of early recurrences in postmenopausal women with early stage breast cancer: Using number needed to treat (NNT) to compare benefit

H. Rugo, G. Dranitsaris, S. Kaura, 2008 .

Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients

G. Dranitsaris, M. Clemons, S. Chia, 2009, Breast Cancer Research and Treatment.

Are community pharmacists equipped to ensure the safe use of oral anticancer therapy in the community setting? Results of a cross-country survey of community pharmacists in Canada

G. Dranitsaris, S. Edwards, J. Edwards, 2014, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

PCN21 NUMBER NEEDED TO TREAT (NNT) ANALYSIS COMPARING BENEFITS OF LETROZOLE WITH ADJUVANT CHEMOTHERAPY IN PATIENTS WITH NODE-POSITIVE BREAST CANCER

H. Rugo, G. Dranitsaris, S. Kaura, 2009 .

Number needed to treat (NNT) to compare benefits of letrozole (LET) with adjuvant chemotherapy (CT) in patients (pts) with node-positive (N+) breast cancer (BC).

H. Rugo, G. Dranitsaris, S. Kaura, 2009, Journal of Clinical Oncology.

Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting

Zhou Wang, G. Dranitsaris, B. Hutton, 2016, Breast Cancer Research and Treatment.

Pharmacoeconomic Analysis of Empirical Therapy with Ceftazidime Alone or Combination Antibiotics for Febrile Neutropenia in Cancer Patients

G. Dranitsaris, A. McGeer, T. Tran, 2012, PharmacoEconomics.

Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs

G. Dranitsaris, M. Vincent, G. Adunlin, 2018, Expert review of pharmacoeconomics & outcomes research.

Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer Agents.

G. Acton, G. Dranitsaris, E. Podack, 2015, Journal of immunotherapy.

Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine

M. Lacouture, G. Dranitsaris, George Dranitsaris, 2014, Breast Cancer Research and Treatment.

Using Filgrastim Efficiently

G. Dranitsaris, 1996, PharmacoEconomics.

Outcomes Assessment of a Pharmacist-Directed Seamless Care Program in an Ambulatory Oncology Clinic

Michael LeBlanc, N. MacKinnon, G. Dranitsaris, 2014, Journal of pharmacy practice.

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events

G. Pond, G. Dranitsaris, M. Clemons, 2014, Breast Cancer Research and Treatment.

Patient monitoring programs in oncology pharmacy practice: A survey of oncology pharmacists in Atlantic Canada

G. Dranitsaris, S. Edwards, Rick Abbott, 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma.

G. Dranitsaris, S. Sutcliffe, 1995, Leukemia & lymphoma.

Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer.

G. Dranitsaris, M. Clemons, D. Cole, 2006, The oncologist.

G. Dranitsaris, E. Amir, K. Dorward, 2011, Drugs.

Health Technology Assessment of Cancer Drugs in Canada, the United Kingdom and Australia: Should the United States Take Notice?

G. Dranitsaris, G. Papadopoulos, 2015, Applied Health Economics and Health Policy.

Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain.

D. Cella, D. Eton, G. Dranitsaris, 2009, Journal of pain and symptom management.

Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.

I. Tannock, A. Oza, G. Dranitsaris, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost-Utility A nalysis o f C hemotherapy U sing P aclitaxel, Docetaxel, o r V inorelbine f or P atients W ith Anthracycline-Resistant B reast C ancer

G. Dranitsaris, A. Puodziunas, 1999 .

The prolyl‐hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia

Tim Crook, G. Dranitsaris, T. Crook, 2010, European journal of haematology.

Oral therapies for the treatment of pulmonary arterial hypertension

G. Dranitsaris, S. Mehta, 2009, Applied health economics and health policy.

Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia.

G. Dranitsaris, T. Crook, H. Coley, 2009, Leukemia research.

Using pharmacoeconomic modelling to determine value-based pricing for new pharmaceuticals in malaysia.

G. Dranitsaris, I. Truter, M. Lubbe, 2011, The Malaysian journal of medical sciences : MJMS.

Does prolonging the time to prostate cancer surgery impact long-term cancer control: a systematic review of the literature.

M. Gleave, F. Saad, A. Finelli, 2006, The Canadian journal of urology.

Surgical wait times for patients with urological cancers: a survey of Canadian surgeons.

M. Gleave, A. Finelli, G. Dranitsaris, 2006, The Canadian journal of urology.

Does prolonging the time to testicular cancer surgery impact long-term cancer control: a systematic review of the literature.

C. Morash, G. Dranitsaris, L. Klotz, 2006, The Canadian journal of urology.

Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use.

G. Dranitsaris, J. Lipton, A. Viswabandya, 2021, Hematology/oncology and stem cell therapy.

The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting

A. Molassiotis, M. Aapro, G. Dranitsaris, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta analysis of the literature

G. Dranitsaris, B. Zanke, E. Green, 2005 .

Sterile versus nonsterile gloves for repair of uncomplicated lacerations in the emergency department: a randomized controlled trial.

G. Dranitsaris, T. Rutledge, Gregory J. Francis, 2004, Annals of emergency medicine.

A cost-utility analysis of risk model-guided versus physician’s choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach

Zhou Wang, D. Coyle, G. Dranitsaris, 2017, Supportive Care in Cancer.

Identifying cancer patients at high risk for chemotherapy-induced nausea and vomiting (CINV): the development of a prediction tool

M. Aapro, G. Dranitsaris, M. Clemons, 2016 .

Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting.

G. Dranitsaris, M. Clemons, P. Wheatley‐Price, 2012, The journal of supportive oncology.

A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting

G. Dranitsaris, B. Hutton, M. Clemons, 2020, Breast.

Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey.

B. Fitzgerald, G. Dranitsaris, S. Saibil, 2010, Current oncology.

Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer.

A. Oza, G. Dranitsaris, H. Sutherland, 1997, Gynecologic oncology.

Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool.

A. Shah, G. Dranitsaris, M. Vincent, 2007, Clinical colorectal cancer.

Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes

G. Dranitsaris, D. Liew, P. McEwan, 2018, ClinicoEconomics and outcomes research : CEOR.

The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines

K. Gelmon, G. Dranitsaris, D. Rayson, 2008, Breast Cancer Research and Treatment.

Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death

S. Verma, E. Rakovitch, G. Dranitsaris, 2005, Breast Cancer Research and Treatment.

Mark Clemons patients with metastatic breast cancer Recent developments in bisphosphonates for

G. Dranitsaris, M. Clemons, M. C. Gainford, 2005 .

Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer

G. Dranitsaris, S. Hopkins, Wayne Cottrell, 2009, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy.

G. Dranitsaris, T. Tran, 1995, European journal of cancer.

Impact of aprepitant on emesis control, dose intensity, and recurrence-free survival in a population-based cohort of head and neck cancer patients receiving high-dose cisplatin chemotherapy.

G. Dranitsaris, W. Cheung, S. Makarenko, 2014, The Journal of community and supportive oncology.

Identifying Patients at High Risk for Neutropenic Complications During Chemotherapy for Metastatic Breast Cancer With Doxorubicin or Pegylated Liposomal Doxorubicin: The Development of a Prediction Model

K. Gelmon, G. Dranitsaris, D. Rayson, 2008, American journal of clinical oncology.

The role of urinary N-telopeptides in evaluating the palliative benefit of bisphosphonates in metastatic breast cancer

G. Dranitsaris, M. Clemons, C. Simmons, 2007 .

Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide

H. Scher, M. Lacouture, G. Dranitsaris, 2022, The Journal of urology.

The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs.

G. Dranitsaris, I. Truter, Wayne Cottrell, 2012, Journal of evaluation in clinical practice.

The autologous blood and marrow transplant long-term follow-up clinic: a model of care for following and treating survivors of autotransplant

G. Dranitsaris, A. Schimmer, A. Keating, 2002, Supportive Care in Cancer.

Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.

M. Lacouture, G. Dranitsaris, M. Vincent, 2012 .

A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: an assessment of amifostine cytoprotection

G. Dranitsaris, 1997, Supportive Care in Cancer.

Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer

G. Dranitsaris, T. Hsu, 1999, Supportive Care in Cancer.

The impact of practice guidelines and funding policies on the use of new drugs in advanced non-small cell lung cancer.

G. Dranitsaris, B. Zanke, W. Evans, 2005, Journal of evaluation in clinical practice.

Therapeutic preference for Alzheimer’s disease treatments: a discrete choice experiment with caregivers and neurologists

A. Atri, G. Dranitsaris, Quanwu Zhang, 2023, Alzheimer's Research & Therapy.

Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.

G. Dranitsaris, M. Clemons, S. Gertler, 2016, JAMA oncology.

A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy

G. Dranitsaris, M. Clemons, D. Cole, 2008, Breast Cancer Research and Treatment.

Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy

G. Dranitsaris, S. Schmitz, R. Broom, 2013, Journal of Cancer Research and Clinical Oncology.

Using decision modeling to determine pricing of new pharmaceuticals: The case of neurokinin-1 receptor antagonist antiemetics for cancer chemotherapy

G. Dranitsaris, P. Leung, Pauline P. Leung, 2004, International Journal of Technology Assessment in Health Care.

PAMIDRONATE FOR THE PREVENTION OF SKELETAL- RELATED EVENTS IN MULTIPLE MYELOMA

G. Dranitsaris, 1999, International Journal of Technology Assessment in Health Care.

Cost effective evaluation of a stability study.

G. Dranitsaris, S. Walker, J. Iazzetta, 1987, The Canadian Journal of Hospital Pharmacy.

The development of a value-based pricing index for new drugs in metastatic colorectal cancer.

G. Dranitsaris, I. Truter, M. Lubbe, 2011, Journal of Clinical Oncology.

A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting

G. Dranitsaris, S. Blau, C. Faria, 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Are Estring® and Vagifem® equally effective and safe for the treatment of urogenital atrophy in breast cancer patients on aromatase inhibitor therapy?

M. Dowsett, G. Dranitsaris, T. Colgan, 2012, Clinics in oncology.

The Economic Value of a New Insulin Preparation, Humalog® Mix 25™

G. Dranitsaris, L. Grossman, C. Longo, 2000, PharmacoEconomics.

Bioavailability of iron in oral ferrous sulfate preparations in healthy volunteers.

M. A. Manuel, G. Dranitsaris, S. Walker, 1989, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

CLINICAL RESEARCH O.6 Pre-operative exercise and pyrexia as modifying factors in malignant hyperthermia

A. Bjorksten, G. Dranitsaris, N. Voermans, 2021, Neuromuscular Disorders.

Management of patients with Cushing's disease: a Canadian cost of illness analysis.

G. Dranitsaris, A. Lacroix, M. Hurry, 2014, Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique.

Extended Dalteparin Prophylaxis for Venous Thromboembolic Events

G. Dranitsaris, Reginald E. Smith, W. Bartle, 2012 .

Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.

G. Dranitsaris, Reginald E. Smith, W. Bartle, 2009, American journal of cardiovascular drugs : drugs, devices, and other interventions.

Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacement.

V. Jelinčić, G. Dranitsaris, Y. Choe, 2011 .

Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea.

G. Dranitsaris, S. Dowden, J. Maroun, 2007 .

Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer Agents.

G. Acton, G. Dranitsaris, E. Podack, 2015, Journal of immunotherapy.

A phase 2 trial exploring the effects of high‐dose (10,000 IU/day) vitamin D3 in breast cancer patients with bone metastases

G. Dranitsaris, M. Clemons, R. Vieth, 2010, Cancer.

Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor–positive breast cancer.

S. Chandarlapaty, M. Robson, M. Lacouture, 2022, Journal of Clinical Oncology.

What is a new drug worth? An innovative model for performance-based pricing.

G. Dranitsaris, K. Dorward, H. Schipper, 2015, European journal of cancer care.

Improving patient access to cancer drugs in India: Using economic modeling to estimate a more affordable drug cost based on measures of societal value

G. Dranitsaris, I. Truter, M. Lubbe, 2011, International Journal of Technology Assessment in Health Care.

Patient perceptions about potential side effects and benefits from chemotherapy agents.

G. Dranitsaris, M. Clemons, S. Gertler, 2013 .

Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer

G. Dranitsaris, S. Hopkins, Wayne Cottrell, 2009, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Dovitinib in first-line renal cell carcinoma: An investigation into tumour gene status and correlation with efficacy: A phase II clinical trial.

G. Dranitsaris, M. McKeage, P. Fong, 2014 .